Skip to main content
Incuron, LLC

 Development, preclinical investigations and
  clinical trials of innovative medicines for
   treatment of cancer and auto-immune
diseases, based on Curaxins - a novel class of
               chemical structures




                   2012
Applicant’s Characteristics
           CEO – Andrey A. Leonov, PhD
           Deputy General Manager– Roman V. Ivanov, PhD.
           Director of pre-clinical programs – Ramiz M. Salimov, D. Sci.
           Clinical Operations Manager – Polina A. Shpigotskaya, PhD.
           Scientific Manager –Andrei V. Gudkov, prof., D.Sci.
           Project Manager – Ludmila V. Khristoforova, PhD




Persons providing assistance to Applicant in implementing Innovation Project:
Bioprocess Capital Partners managing company provides assistance to Incuron LLC project with GR/PR issues and regulatory procedures in Russia
ŠœŠµŠ“ŠøŃ†ŠøŠ½ŃŠŗŠøŠ¹ Довет компании, ŃŠ¾ŃŃ‚Š¾ŃŃ‰ŠøŠ¹ ŠøŠ· Š²ŠµŠ“ŃƒŃ‰ŠøŃ… врачей-онкологов России Šø ДША:
       Andrei Vladimirovich Gudkov – Sc.D., Professor, Senior Vice-President, Abstract Science; Head, Department of Cell Stress Biology, Roswell
       Park.
       Sergey Alekseevich Tjulandin – MD, Professor, Deputy Director, Head, Department of Clinical Pharmacology and Chemotherapy, Russian
       Oncological Scientific Research Center under the Russian Academy of Medical Sciences
       Vladimir Mikhailovich Moiseenko – MD, Professor, Honoured Doctor of the RF; Deputy Director for Science; Head, Department of
       Biotherapy and Bone Marrow Transplantation, Prof. Petrov Oncology Research Institute under Federal Agency of Health and Social
       Development of the RF
       Valeriy Georgievich Savchenko – MD, Professor, corresponding member, Russian Academy for Medical Sciences; Deputy Director for
       Science, Haematological Research Center; Director, BMT and Molecular Haematology Research Institute; Scientific Adviser, Department
       of Chemotherapy for Hemoblastosis, Hematopoiesis depression and BMT
       Alex Adjei – MD, Professor, Senior Vice-President for Clinical Research; Chief, Department for Clinical Research Phase I, Roswell Park,
       member of medical expert councils at many BigPharma large Western Companies.
       Preet Chaudhary – MD, Professor, Deputy Director, University of Relaying Research at Pitsburg Cancer Institute; Director of Haematology
       Programs at Pitsburg University, USA
Innovation project overview
The aim of the project is to become a global pharmaceutical company which
develops and bring to the Russian and international markets novel anti-cancer
medicines

 Curaxins – small molecules with potentially wide spectrum of therapeutic use as pharmaceuticals
 which showed efficacy against various malignant tumors, autoimmune diseases, also demonstrated anti-
 inflammatory activity
 Advances technologies developed by American Company Cleveland Biolabs, Inc.
 Existing curaxins are represented by two classes of chemical compounds:
       ―Based on aminoacridine structure (innovative by their use)
       ―Based on carbazole structure (innovative by chemical class of molecules)
 Curaxin’s uniqueness is based on their ability to repair the abnormal activity of three key signaling
 pathways simultaneously in tumor cells, providing selective anti-tumor activity (through inhibition of
 chromatin protein complex FACT)
 Highly potent and selective pharmaceuticals against several types of malignant tumors
 Curaxins potentially could also be developed into novel pharmaceuticals against some autoimmune
 diseases and inflammatory conditions
Product and (or) technology description
 The ultimate goal of the Project is the use of breakthough biomedical technologies of the Clevеland Biolabs, Inc.
  for development and launch on the Russian markets (5 years) and USA (7 years) of fundamentally novel effecient
  anticancer medicines with the unique effect mechanism.

 Curaxins are synthetic small molecules with previously unknown properties. Their structure is patentable.

 Animal tests demonstrated favorable toxicological and pharmacological characteristics of curaxins.

 Their anti-tumor activity was proven by preclinical studies of mouse models and of human tumor xenograft
  models performed in Russian Federation and in the USA.

 Structural analysis resulted in establishing an algorithm predicting with high degree of accuracy the functionality
  of Curaxin-like molecules. These data show that the structure of DNA is not damaged by curaxins.


                                                                                           Curaxin




              Active compounds                                                            Doxorubicin




                                                                                 No DNA damage by Curaxins
             Inactive compounds                              DNA binding
Technical description of the product
 As transforming to malignant tumors cancer cells undergo changes in
  the main signaling cascades responsible for survival. Among cascades
  the functioning of which is disturbed almost in all cells of malignant
  tumors, the most significant is the cascade of tumor suppress p53
  (depressed), NF-ĪŗB and heat shock proteins cascades (activated).                  Live tumor cell                      Dead tumor cell

                                                                                                      Curaxins
 Curaxins enable to activate p53 cascade and simultaneously suppress
  NF-ĪŗB and HSF-1 cascades(which induce heat shock cascade). High                         activator              Drugs exist
  frequency of deregulation of those cascades in different oncological
  diseases suggests that significant proportion of tumors are treatable                  inhibitor               Drugs exist

  by combinational Curaxins.                                                                                     Drugs under development
                                                                                         inhibitor               but not on the market yet




         Description                      Curaxin CBL0102                               Curaxin CBL0137
   Class of compound                 Aminoaсridines                               Carbazoles

   Novelty of the molecule           Have been applied for treatment of malaria   First-in-class molecule
                                     during many years
   Suggested molecular effect        1) Activation р53                            1) Activation p53
   mechanism                         2) Inhibition NF-kB                          2) Inhibition NF-kB
                                     3) Inhibition HSF1                           3) Inhibition HSF1
   Distribution in organism          Predominantly accumulates in the liver       Predominantly accumulates in lungs, spleen,
                                                                                  thymus, kidneys
   Relative anticancer activity on   **                                           ***
   animals
Project finance.
           1 tranche                                 2 tranche                             3 tranche

      175 570 thousand                        194 000 thousand                      179 927 thousand
           rubles                                  rubles                                rubles.


      34 000 thousand                         116 000 thousand
           rubles                                  rubles
      (grant of Skolkovo)                      (grant of Skolkovo)
 Preclinical studies CBL0137 to    Carry out of Phase 1 of Clinical trials    Phase 2 of Clinical Trials (RF)
  obtain a permit for phase 1B of   of CBL0137                                  Phase 1 of Clinical Trials in
  Clinical Trials in Russia         Completion of R&D                          RF and US as a monotherapy
 Research and Development of       Preclinical Trials of CBL0137 in           and as a complex
  CBL0137 and its analogs           complex                                     Phase 1 of Clinical trials of
 Phase 1B of Clinical Trial of     Preclinical               Trial       of   one of the analogs of
 CBL0102 in Russia                 intravenous formulation of CBL0137 in       CBL0137             (carbazolic
                                    US                                          compound)       for     further
                                    Completion of Phase 1B of Clinical         investigations of autoimmune
                                    trials of CBL0102                           diseases and cancer
                                    Start of Phase 2 of Clinical trials of
                                    CBL0102
                                    The study of carbazolic analogs for
                                    several indicators, including Preclinical
                                    and Clinical trials of hit compounds                                  6
Method of commercialization and competitive
              advantages, reasons for the interest of consumers in
                       the product and (or) technology
• Competitive advantages of the product:
      ―Curaxin’s property to target several key pathways simultaneously in cancer cells that decreases the potency of
       tumor cells to form drug resistance and increases anti-tumor efficacy (it was proven experimentally).
      ―As opposed to conventional anti-cancer drugs, curaxins combine high efficacy and safety
      ―As opposed to conventional anti-cancer drugs, curaxins do not induce DNA damage


                                                                       Market of state procurement (Russia)
            Commercialization

                                                                         Medical insurance market (USA)



• Reasons for the interest of consumers in the product:
      ―Innovative medicines against several types of cancer including orphan disease – nephroma and auto-immune
       disease – systemic lupus erythematosus; that gives specific social status to the developed medicines
      ―The novel class of medicines that fundamentally differ by effect mechanism and efficiency from the current and
       developing by other companies
Project progress
                                       2012               2013             2014              2015         2016            2017             2018           2019              2020            2021        2022

                 CT 1 (RF)                   CT 1 (RF)
                 CT 2 (RF)                                                CT 2 (RF)
  CBL0102




                 CT 3 (RF)                                                                               CT 3 (RF)                                             Sales (RF)

               CT 1 (USA)                                                                           CT 1 (USA)
               CT 2 (USA)                                                                                                     CT 2 (USA)
               CT 3 (USA)                                                                                                                                 CT 3 (USA)                      Sales (USA)

                                                    Pre-CT (RF)
              Pre-CT (RF)
                                                              CT 1 (RF)
                CT 1 (RF)
                CT 2 (RF)                                                                                         CT 2 (RF)
   CBL0137




                CT 3 (RF)                                                                                                                     CT 3 (RF)
                                                                                                                                                                             Sales (RF)
             Pre-CT (USA)                   Pre-CT (USA)
               CT 1 (USA)                                             CT 1 (USA)
                                                                                                                 CT 2 (USA)
               CT 2 (USA)
               CT 3 (USA)                                                                                                                    CT 3 (USA)
                                                                                                                                                                            Sales (USA)

                 SRD (RF)                   SRD (RF)
Analogues




              Pre-CT (RF)                                  Pre-CT (RF)
CBL0137




                CT 1 (RF)                                                        CT 1 (RF)
                CT 2 (RF)                                                                           CT 2 (RF)

                CT 3 (RF)                                                                                                        CT 3 (RF)                                   Sales (RF)


                            194 mln. RUR
                                                         110,7 mln. RUR
                            116 mln. RUR
                             ( Skolkovо )                                  69,2 mln. RUR.

                                                                                              Approval